Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bisantrene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 8/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | NQO1 | P15559 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 0.62 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.56 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.56 |
| ▸ | ASIC1 | P78348 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 6/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bisantrene SCHEMBL29398210 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| Bisantrene SCHEMBL7207049 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| Bisantrene SCHEMBL8906393 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| Bisantrene SCHEMBL1649622 | 0.98 | ADRA2A (0.97) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| Bisantrene SCHEMBL17819003 | 0.98 | ADRA2A (0.97) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| Bisantrene SCHEMBL2852448 | 0.98 | ADRA2A (0.97) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| Bisantrene SCHEMBL29665174 | 0.98 | ADRA2A (0.97) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| Bisantrene SCHEMBL4773 | 0.98 | ADRA2A (0.97) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| Bisantrene SCHEMBL17819004 | 0.98 | ADRA2A (0.97) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| SCHEMBL24610440 | 0.93 | ADRA2A (0.86) | ADRA2AADRA1AHTR1ACHRM2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 40124 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260085100-A1 | METHODS OF ANTIGEN PRODUCTION | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2026-03-26 | — | — | US | claimed |
| US-20260076941-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | UNIV GEORGETOWN (US) | 2026-03-19 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4698185-A1 | METHODS AND SYSTEMS FOR IMPROVING ANTI-CANCER THERAPIES | Osasuna Therapeutics SA (CH) | 2026-02-25 | — | — | EP | claimed |
| EP-0844891-A1 | HYPER COMB-BRANCHED POLYMER CONJUGATES | DENDRITECH, INC. (US) | 1998-06-03 | — | — | EP | claimed |
| WO-1997043289-A1 | LARGE SYNTHETIC COMPOUNDS BASED ON ELECTRON DONOR AND ELECTRON ACCEPTOR INTERACTIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1997-11-20 | — | — | WO | claimed |
| WO-1997006833-A9 | HYPER COMB-BRANCHED POLYMER CONJUGATES | — | 1997-04-10 | — | — | WO | claimed |
| WO-1997006833-A1 | HYPER COMB-BRANCHED POLYMER CONJUGATES | DENDRITECH, INC. (US) | 1997-02-27 | — | — | WO | claimed |
| EP-0616813-A2 | Antitumor mitoxantrone polymeric compositions | AMERICAN CYANAMID COMPANY (US) | 1994-09-28 | — | — | EP | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| US-5288503-A | WATER-PERMEABLE DIFFUSION BARRIER OF POLYVINYL ALCOHOL | SRCHEM INCORPORATED (US) | 1994-02-22 | — | — | US | claimed |
| US-5260066-A | Cryogel bandage containing therapeutic agent | SRCHEM INCORPORATED (US) | 1993-11-09 | — | — | US | claimed |
| US-5143661-A | Silicone-hardened pharmaceutical microcapsules | AMERICAN CYANAMID COMPANY (US) | 1992-09-01 | — | — | US | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |